养生
医学
卡铂
药代动力学
肺癌
人口
依托泊苷
加药
分配量
内科学
体重
药理学
肿瘤科
化疗
环境卫生
顺铂
作者
Peng R. Chen,Yanyan Zhang,Yike Wang,Ke Ma,Wei Shi,Nassim Djebli,Kai Shen
摘要
Adebrelimab, a novel anti-PD-L1 antibody, has been approved by the National Medical Products Administration of China as an intravenous infusion for use in combination with carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer in 2023. A two-compartment model with empirical time-varying CL for adebrelimab was established based on data from 263 patients receiving body weight-based doses from two clinical studies. Significant covariate effects of baseline body weight, albumin levels, tumor size, neutrophil counts, and presence of anti-drug antibodies were identified on CL of debrelimab, none of which were clinically significant or warranted dose adjustment. The degree of decrease in CL was higher in patients who responded to treatment with adebrelimab than in non-responders. Adebrelimab exposures (AUC, C
科研通智能强力驱动
Strongly Powered by AbleSci AI